Concord Biotech share price jumps on USFDA nod 2026

What triggered the move in Concord Biotech

Concord Biotech shares rose sharply on Wednesday after the company said it received approval from the US Food and Drug Administration (USFDA) for an Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets. The approval is for two dosage strengths, 5 mg and 10 mg. Trading updates across reports showed the stock rising about 6% intraday and touching around a four-month high near Rs 1,349.90-1,350 on the BSE. The move extended gains for a second session, taking the two-day rise to nearly 13% as per one market update.

The company communicated the development through an exchange filing, including a disclosure under SEBI Regulation 30. Concord Biotech is listed on NSE as CONCORDBIO and on BSE as 543960, and operates in the Pharmaceuticals and Biotechnology segment within healthcare.

USFDA approval details: ANDA for Tofacitinib Tablets

Concord Biotech said the USFDA has granted final approval for its ANDA for Tofacitinib Tablets. The approval pertains specifically to 5 mg and 10 mg strengths. Tofacitinib is used across multiple inflammatory conditions, and the company listed a broad set of indications.

In its filing, Concord Biotech stated the tablets are indicated for adult patients with moderately to severely active rheumatoid arthritis (RA). The company also cited use in active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and moderately to severely active ulcerative colitis (UC). It additionally mentioned active polyarticular course juvenile idiopathic arthritis (pcJIA). The disclosure positioned the product as part of the company’s US generics strategy.

Why Tofacitinib matters commercially

Market size estimates cited alongside the announcement put the combined US market for Tofacitinib Tablets (both strengths) at approximately US$100 million, based on IQVIA estimates mentioned in the report. That figure explains why the approval drew immediate investor attention.

The branded reference drug was cited as Xeljanz (Pfizer), with patent expiry framed as opening a generic opportunity. While Concord Biotech did not provide a launch timeline in the provided text, it did state it plans to capitalise on attractive market opportunities, enhance product offerings, and support growth in the US and international markets following the approval.

Stock price reaction: intraday highs and recent levels

The market reaction was visible across multiple reported price points on Wednesday and nearby sessions. One update said the stock rose up to 5.33% to around Rs 1,340 and hit an intraday high of Rs 1,349.90 on Wednesday, June 10, 2026. Another line said shares surged over 6% to a day’s high of Rs 1,350 on the BSE after the announcement.

Separately, a quoted “current share price” snapshot showed Rs 1,353.8. Another market snapshot referenced “current” at Rs 1,336.20 after an intraday high of Rs 1,349.90, reflecting typical cooling-off after a spike. A later trading reference cited Rs 1,337, along with a stated intraday range of Rs 1,297.70 to Rs 1,342.70, and a 52-week range of Rs 987.00 to Rs 2,150.40.

Second ANDA approval within a week

The Tofacitinib approval was described as Concord Biotech’s second major USFDA ANDA approval within a week. The earlier approval mentioned was for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, disclosed on June 3, 2026 (with a BSE timestamp also referenced as June 2, 2026).

The US market opportunity cited for Mycophenolate Mofetil for Oral Suspension was estimated at around US$10 million. Taken together, the two back-to-back approvals signal an active period for the company’s filings and product pipeline execution in the US generics channel, based on the information provided.

Key facts table

Valuation snapshot from the provided data

Alongside the price move, the provided dataset included a market capitalisation figure of Rs 14,162.94169752 crore, calculated based on the latest share price in that snapshot. It also included valuation ratios: a PE ratio of 53.7969401947149 and a P/B ratio of 7.01221880940418.

These numbers help frame how the market is valuing Concord Biotech around the time of the USFDA update, although the article text does not link the ratios to any change in earnings expectations. The immediate driver discussed was the regulatory milestone and its potential to broaden the company’s product offerings in the US.

Market impact: what changes for investors and the business

For investors, the most direct impact was a sharp intraday move of roughly 5%-6% and the stock printing levels described as an over four-month high. For the company, the approval expands the set of USFDA-cleared products it can potentially offer through the US generics route.

The estimated ~US$100 million market size for Tofacitinib Tablets across both strengths provides context for why the announcement was treated as price-sensitive. The company also linked the approval to its intent to support growth in the US and international markets, indicating a broader commercial push beyond a single product.

Background: company profile and positioning

Concord Biotech was incorporated in 1984 and is described as an India-based, R&D-driven biopharma company. It is also identified as a manufacturer of fermentation-based APIs across immunosuppressants and oncology.

That positioning aligns with the nature of the products mentioned in the approvals, including immunosuppressant-related therapies. The USFDA approvals are particularly important in the Indian pharma context because they expand addressable markets and signal compliance readiness for regulated geographies.

Conclusion

Concord Biotech’s USFDA approval for Tofacitinib Tablets (5 mg and 10 mg) drove a strong market reaction, with the stock rising about 6% intraday and touching around Rs 1,349.90-1,350 in the session. The company cited a combined US market opportunity of about US$100 million for the product across strengths, and the disclosure came under SEBI Regulation 30 on June 10, 2026.

The next signposts for investors, based on the provided information, will be any further exchange filings on commercialisation plans and additional regulatory updates, following the company’s recent sequence of ANDA approvals.